Janus
kinase (Jak) is a family of non-tyrosine receptor kinases, which play
a major role in cytokine signaling. Binding of cytokines (ligand) to
receptor results in receptor dimerization and ultimately activates
Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT
(Signal Transducer and Activator of Transcription proteins) and STAT
dimer carries out the transcription of genes which are critical for
signal cascade involved in inflammatory and immune response.
Therefore, Janus kinase is used as a target in treatment of
autoimmune disorders such as rheumatoid arthritis.
To
Have A Snippet Of The Report, Request Sample:
https://www.coherentmarketinsights.com/insight/request-sample/2553
Janus
Kinase Inhibitor Market Drivers
Jak
inhibitors are increasingly preferred for industrial research due to
their critical role in immune response signaling. For instance, in
June 2018, Eli Lilly and Company announced approval from the U.S.
Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an
oral medication for rheumatoid arthritis in adults. Approval was
granted for use of baricitinib in combination with methotrexate (MTX)
or other disease-modifying antirheumatic drugs (DMARDs) or as
monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1
and 2) and decreases the production of inflammatory cytokines,
thereby inhibiting inflammatory response. Therefore, increasing
launch of new drugs is expected to fuel the global janus kinase
inhibitor market growth over the forecast period.
Psoriatic
arthritis is a form of arthritis, which is characterized by red
patches of skin with silvery scales. Tofacitinib is a janus kinase
inhibitor, which modulates cytokines that are required for signaling
of inflammatory and immune response. Inclusion of new treatment
options is expected to boost the global janus kinase inhibitor market
growth over the forecast period. For instance, in December 2017,
Pfizer Inc. received approval from the U.S. FDA for XELJANZ
(TOFACITINIB) for treatment of adult patients suffering from
psoriatic arthritis (PsA).
Janus
Kinase Inhibitor Market Regional Analysis
The
Janus kinase pathway mediates intracellular signaling of over sixty
cytokines. Dysregulation of cytokines causes systemic lupus
erythematosus (SLE) -- an autoimmune disorder and chronic disease,
which is characterized by inflammation of connective tissues such as
cartilage and blood vessel lining. According to National Center for
Biotechnology Information (NCBI), the highest prevalence and
incidence of SLE was in recorded in North America (23.2/100 000
person) during the period August 2013- September 2016. Therefore,
high prevalence of SLE is expected to boost North America janus
kinase inhibitor market growth over the forecast period.
Janus
Kinase Inhibitor Market Key Players
Some
of the key players operating in the global Janus kinase inhibitor
market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer
Inc., Baxter International Inc., Novartis International AG, Gilead
Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte
Corporation.
Janus
Kinase Inhibitor Market Taxonomy
The
global janus kinase inhibitor market is segmented on the basis of
drugs, indication, distribution channel and regions.
By
Drugs
-
Baricitinib
-
Tofacitinib
-
Ruxolitinib
-
Pipeline drugs
-
Peficitinib
By
Indication
-
Rheumatoid arthritis
-
Psoriatic arthritis
-
Systemic lupus erythematosus
-
Others
Get
Full Access of This Business Report:
https://www.coherentmarketinsights.com/ongoing-insight/janus-kinase-inhibitor-market-2553
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment